Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil.
Gensburger O, Van Schaik RH, Picard N, Le Meur Y, Rousseau A, Woillard JB, Van Gelder T, Marquet P. Gensburger O, et al. Among authors: van gelder t, van schaik rh. Pharmacogenet Genomics. 2010 Sep;20(9):537-43. doi: 10.1097/FPC.0b013e32833d8cf5. Pharmacogenet Genomics. 2010. PMID: 20679962 Free PMC article.
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T. Hesselink DA, et al. Among authors: van der werf m, van gelder t, van schaik rh, van der heiden ip. Clin Pharmacol Ther. 2003 Sep;74(3):245-54. doi: 10.1016/S0009-9236(03)00168-1. Clin Pharmacol Ther. 2003. PMID: 12966368
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.
Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, van der Werf M, Weimar W, Mathot RA. Hesselink DA, et al. Among authors: van dam t, van gelder t, van der werf m, van schaik rh, van der heiden ip. Clin Pharmacol Ther. 2004 Dec;76(6):545-56. doi: 10.1016/j.clpt.2004.08.022. Clin Pharmacol Ther. 2004. PMID: 15592326
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.
Hesselink DA, van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DR, Pisarski P, Le Meur Y, Mamelok RD, van Gelder T. Hesselink DA, et al. Among authors: van agteren m, van gelder t, van schaik rh. Pharmacogenet Genomics. 2008 Apr;18(4):339-48. doi: 10.1097/FPC.0b013e3282f75f88. Pharmacogenet Genomics. 2008. PMID: 18334918 Clinical Trial.
AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
van Agteren M, Armstrong VW, van Schaik RH, de Fijter H, Hartmann A, Zeier M, Budde K, Kuypers D, Pisarski P, Le Meur Y, van der Werf M, Mamelok RD, Oellerich M, van Gelder T. van Agteren M, et al. Among authors: van der werf m, van gelder t, van schaik rh. Ther Drug Monit. 2008 Aug;30(4):439-44. doi: 10.1097/FTD.0b013e318180c709. Ther Drug Monit. 2008. PMID: 18641546 Clinical Trial.
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
Bijl MJ, van Schaik RH, Lammers LA, Hofman A, Vulto AG, van Gelder T, Stricker BH, Visser LE. Bijl MJ, et al. Among authors: van gelder t, van schaik rh. Breast Cancer Res Treat. 2009 Nov;118(1):125-30. doi: 10.1007/s10549-008-0272-2. Epub 2009 Feb 3. Breast Cancer Res Treat. 2009. PMID: 19189212
423 results